Risks

Negative interest coverage and near-breakeven net debt to EBITDA indicate financing remains sensitive versus profitable peers, limiting flexibility if capital markets tighten.

A debt-to-equity ratio of 1.87 versus many biotech peers with lighter balance sheets raises refinancing and dilution risk if clinical timelines extend or funding windows narrow.

Current and quick ratios of 1.82 provide near-term liquidity support, but they still trail cash-rich development peers that can fund longer trial cycles without external capital.

The absence of reported FCF margin keeps cash burn visibility limited versus peers with clearer operating leverage, making execution risk harder to absorb if trial spending rises.

Opportunities

A relatively strong current ratio versus many pre-revenue peers supports trial continuity and reduces near-term funding pressure, improving positioning in a capital-intensive sector.

Negative net debt to EBITDA suggests modest net leverage versus peers, which can preserve optionality for development spending if clinical catalysts improve.

If pipeline milestones progress, IMNN can benefit from the sector’s binary re-rating dynamics, where positive data often drives sharper upside than in more mature peers.

Compared with leveraged small-cap biotech peers, the company’s liquidity profile may better support milestone execution, increasing the chance of surviving to value-inflecting readouts.

Overall Score

IMNN’s forward positioning is supported by adequate liquidity and modest net leverage, but financing sensitivity, leverage, and limited cash-flow visibility keep peer-relative risk meaningful.